

10/516,079

FILE 'HOME' ENTERED AT 12:37:38 ON 03 AUG 2006

=> b reg
COST IN U.S. DOLLARS
FULL ESTIMATED COST
SINCE FILE ENTRY TOTAL
4.62 4.62

FILE 'REGISTRY' ENTERED AT 12:50:32 ON 03 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 1 AUG 2006 HIGHEST RN 897851-29-5
DICTIONARY FILE UPDATES: 1 AUG 2006 HIGHEST RN 897851-29-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s mcmpefttdhmarkdcdccgkgrgkcygpcqlcr/sqep
5 MCMPCFTTDHMARKDCCGKGRGKCYGPOCLCR/SQEP
L1 64941 SQL=36
5 MCMPCFTTDHMARKDCCGKGRGKCYGPOCLCR/SQEP
(MCMPCFTTDHMARKDCCGKGRGKCYGPOCLCR/SQEP AND SQL=36)

=> s mcmpefttdhmarkdcdccgkgrgkcygpcqlcr/sqep
5 MCMPCFTTDHMARKDCCGKGRGKCYGPOCLCR/SQEP
L2 64941 SQL=36
(MCMPCFTTDHMARKDCCGKGRGKCYGPOCLCR/SQEP AND SQL=36)

=> b caplus uspatfull pctfull biosis scisearch medline
COST IN U.S. DOLLARS
FULL ESTIMATED COST
SINCE FILE ENTRY TOTAL
15.42 20.04

FILE 'CAPLUS' ENTERED AT 12:52:22 ON 03 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 12:52:22 ON 03 AUG 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 12:52:22 ON 03 AUG 2006
COPYRIGHT (C) 2006 Univencio

FILE 'BIOSIS' ENTERED AT 12:52:22 ON 03 AUG 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'SCISEARCH' ENTERED AT 12:52:22 ON 03 AUG 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 12:52:22 ON 03 AUG 2006

=> s l2
'SQEP' IS NOT A VALID FIELD CODE
'SQEP' IS NOT A VALID FIELD CODE
L3 53 L2

=> dup remo l3
PROCESSING COMPLETED FOR L3
L4 46 DUP REMO L3 (7 DUPLICATES REMOVED)

=> s l4 and cancer
L5 18 L4 AND CANCER

=> s l4 and tumor?
L6 24 L4 AND TUMOR?

=> s l6 or l5 and chemotherap?
L7 24 L6 OR L5 AND CHEMOTHERAP?

=> s l6 and chemotherap?
L8 3 L6 AND CHEMOTHERAP?

=> s l5 and chemotherap?
L9 3 L5 AND CHEMOTHERAP?

=> d l8 and l9 1-3 bib abs
L9 IS NOT VALID HERE
For an explanation, enter "HELP DISPLAY".

=> d l8 1-3 bib abs

L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS ON STN
AN 2005:1154420 CAPLUS
DN 143:432633

TI Use of chlorotoxin in diagnosis and treatment of myeloid and lymphoid cell
cancers
IN Alvarez, Vernon L.; Gonda, Matthew A.
PA Transmolecular, Inc., USA
SO PCT Int. Appl., 52 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005099774	A2	20051027	WO 2005-US11523	20050406
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	A3	20060323		
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BS, BY, EG, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2004-559433P 20040406

AB Disclosed is a method of diagnosing and treating myeloproliferative or lymphoproliferative cell disorders, such as cancer, with chlorotoxin and/or derivs., analogs or fragments thereof, which are effective to bind to an inhibit abnormal myeloid or lymphoid cell growth. The chlorotoxin may be conjugated to a second protein, e.g., an antibody binding to a myeloid or lymphoid cancer cell-specific epitope, or a stabilizing protein such as human serum albumin. Alternatively, the chlorotoxin may be conjugated to a cytotoxic agent or chemotherapeutic agent.

L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS ON STN
AN 2003-971907 CAPLUS
DN 140-23219

TI Combination chemotherapy with chlorotoxin for treating cancer
IN Alvarez, Vernon L.; Grimes, Carol A.; Gonda, Matthew A.
PA Transmolecular, Inc., USA
SO PCT Int. Appl., 100 pp.

CO DEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PI WO 2003101474
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KM, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GO, GW, ML, MR, NE, SN, TD, TG
CA 2487425 AA 20031211 CA 2003-2487425 20030602
AU 2003240496 A1 20031219 AU 2003-240496 20030602
EP 1553962 A1 20050720 EP 2003-731504 20030602
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP 200537234 T2 20051208 JP 2004-508829 20030602
US 2006088899 A1 20060427 US 2005-516079 20051102
PRAI US 2002-384171P P 20020531
US 2002-406033P P 20020827
WO 2003-US17410 W 20030602

AB This invention includes compns. and methods for combination chemotherapy, particularly involving at least one chemotherapeutic agent used in combination with chlorotoxin or a derivative thereof. A method for detecting the presence of cancer in a patient comprising administering a detectable amount of labeled chlorotoxin or chlorotoxin derivative are also claimed.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 3 USPATFULL ON STN
AN 2006:104796 USPATFULL
TI Combination chemotherapy with chlorotoxin
IN Alvarez, Vernon L.; Grimes, Carol A.; Gonda, Matthew A.; UNITED STATES
Gonda, Matthew A.; Grimes, Carol A.; UNITED STATES
Grimes, Carol A.; Grimes, Carol A.; UNITED STATES
PI US 2006088899 A1 20060427
AI US 2003-516079 A1 20030602 (10)
WO 2003-US17410 20030602
PRAI US 2002-384171P 20020531 (60)
US 2002-406033P 20020827 (60)

DT Utility
FS APPLICATION
LRP MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004, US
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 15 Drawing Page(s)
LN.CNT 2387

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention includes compositions and methods for combination chemotherapy, particularly involving at least one chemotherapeutic agent used in combination with chlorotoxin or a derivative thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:37:38 ON 03 AUG 2006)

FILE 'REGISTRY' ENTERED AT 12:50:32 ON 03 AUG 2006

L1 5 S MCPCFTTDHOMARKDDCCGKGRKCYGPCLCR/SOEP
L2 5 S MCPCFTTDHOMARKDDCCGKGRKCYGPCLCR/SOEP

FILE 'CAPLUS, USPATFULL, PCTFULL, BIOSIS, SCISEARCH, MEDLINE' ENTERED AT 12:52:22 ON 03 AUG 2006

L3 53 S L2
L4 46 DUP REMO L3 (7 DUPLICATES REMOVED)
L5 18 S L4 AND CANCER
L6 24 S L4 AND TUMOR?
L7 24 S L6 OR L5 AND CHEMOTHERAP?
L8 3 S L6 AND CHEMOTHERAP?
L9 3 S L5 AND CHEMOTHERAP?

=> d 19 1-3 bib abs

L9 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS ON STN
AN 2005:1154420 CAPLUS
DN 143:432633

TI Use of chlorotoxin in diagnosis and treatment of myeloid and lymphoid cell cancers

IN Alvarez, Vernon L.; Gonda, Matthew A.

PA Transmolecular, Inc., USA

SO PCT Int. Appl., 52 pp.

CO DEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PI WO 2005099774 A2 20051027 WO 2005-US11523 20050406
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SI, TJ, TM, TN, TR, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BM, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML,

PRAI US 2004-559433P P 20040406
MR. NE, SN, TD, TG

AB Disclosed is a method of diagnosing and treating myeloproliferative or lymphoproliferative cell disorders, such as cancer, with chlorotoxin and/or derivs., analogs or fragments thereof, which are effective to bind to an inhibit abnormal myeloid or lymphoid cell growth. The chlorotoxin may be conjugated to a second protein, e.g., an antibody binding to a myeloid or lymphoid cancer cell-specific epitope, or a stabilizing protein such as human serum albumin. Alternatively, the chlorotoxin may be conjugated to a cytotoxic agent or chemotherapeutic agent.

L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS ON STN
AN 2003:971907 CAPLUS
DN 140:23219
TI Combination chemotherapy with chlorotoxin for treating cancer
IN Alvarez, Vermont L.; Grimes, Carol A.; Gonda, Matthew A.
PA Transmolecular, Inc., USA
SO PCT Int. Appl., 100 pp.
CODEN: PIXD2

DT Patent
LA English
FAN.CNT 2

PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 2003101474 A1 20031211 WO 2003-US17410 20030602
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GH, GM, HR, HU, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2487425 AA 20031211 CA 2003-2487425 20030602
AU 2003240496 A1 20031219 AU 2003-240496 20030602
EP 1553962 A1 20050720 EP 2003-731504 20030602
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP 200537234 T2 20051208 JP 2004-508829 20030602
US 2006088899 A1 20060427 US 2005-516079 20051102
PRAI US 2002-384171P P 20020531
US 2002-406033P P 20020827
WO 2003-US17410 W 20030602

AB This invention includes compns. and methods for combination chemotherapy, particularly involving at least one chemotherapeutic agent used in combination with chlorotoxin or a derivative thereof. A method for detecting the presence of cancer in a patient comprising administering a detectable amount of labeled chlorotoxin or chlorotoxin derivative are also claimed.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 3 USPATFULL ON STN
AN 2006:104796 USPATFULL
TI Combination chemotherapy with chlorotoxin
IN Alvarez, Vernon L.; Birmingham, AL, UNITED STATES
Gonda, Matthew A.; Birmingham, AL, UNITED STATES
Grimes, Carol A.; Birmingham, AL, UNITED STATES
PI US 2006088899 A1 20060427
AI US 2003-516079 A1 20030602 (10)

WO 2003-US17410 20030602
PRAI US 2002-384171P 20051102 PCT 371 date
US 2002-406033P 20020531 (60)
DT Utility
FS APPLICATION
LREP MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004, US
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 15 Drawing Page(s)
LN.CNT 2387

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention includes compositions and methods for combination chemotherapy, particularly involving at least one chemotherapeutic agent used in combination with chlorotoxin or a derivative thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:37:38 ON 03 AUG 2006)

FILE 'REGISTRY' ENTERED AT 12:50:32 ON 03 AUG 2006
L1 5 S MCMCFTTDHQAARKDCGKGRKCYGQCICR/SQEP
L2 5 S MCMCFTTDHQAARKDCGKGRKCYGQCICR/SQEP

FILE 'CAPLUS, USPATFULL, PCTFULL, BIOSIS, SCISEARCH, MEDLINE' ENTERED AT 12:52:22 ON 03 AUG 2006

L3 53 S L2
L4 46 DUP REMO L3 (7 DUPLICATES REMOVED)
L5 18 S L4 AND CANCER
L6 24 S L4 AND TUMOR?
L7 24 S L6 OR L5 AND CHEMOTHERAP?
L8 3 S L6 AND CHEMOTHERAP?
L9 3 S L5 AND CHEMOTHERAP?

=> s l4 and label?
L10 18 L4 AND LABEL?

=> s l10 and (cancer or tumor or melanoma or carcinoma or hodgkin? or sarcoma or leukemia or lymphoma or neoplas?)
L11 18 L10 AND (CANCER OR TUMOR OR MELANOMA OR CARCINOMA OR HODGKIN? OR SARCOMA OR LEUKEMIA OR LYMPHOMA OR NEOPLAS?)

=> s l4 and (cancer or tumor or melanoma or carcinoma or hodgkin? or sarcoma or leukemia or lymphoma or neoplas?)
L12 27 L4 AND (CANCER OR TUMOR OR MELANOMA OR CARCINOMA OR HODGKIN? OR SARCOMA OR LEUKEMIA OR LYMPHOMA OR NEOPLAS?)

=> d l11 1-18 bib abs

L11 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2006 ACS ON STN
AN 2005:1340302 CAPLUS
DN 144:249518
TI Radiation dosimetry of 131I-chlorotoxin for targeted radiotherapy in Glioma-bearing mice
AU Shen, Sui; Khazaeli, M. B.; Gillespie, G. Yancey; Alvarez, Vernon L.
CS Department of Radiation Oncology, Birmingham, AL, USA
SO Journal of Neuro-Oncology (2005), 71(2), 113-119
CODEN: JNODD2; ISSN: 0167-594X
PB Springer

DT English
LA English
AB

Chlorotoxin, or TM-601, is a peptide derived from the venom of the scorpion *Leiurus quinquestriatus* that specifically binds to malignant brain tumors, but not to normal tissues. Targeted radiotherapy using 131I-Chlorotoxin is promising for post-surgery treatment of brain tumors. This study reports dosimetry results of 131I-Chlorotoxin in athymic nude mice with intracranially implanted human glioma xenografts and projected radiation doses in patients receiving 370 MBq of 131I-Chlorotoxin. 125I/131I-Chlorotoxin were injected into the right brain where D54 MG xenografts were implanted. Mice were sacrificed 24-96 h later. The blood, normal organs, and tumors were weighed and counted to determine 131I-Chlorotoxin concentration. The radiation dose from 131I was calculated based on non-penetrating radiation in the mouse model. Assuming similar tissue uptake in mice and patients, radiation doses for patients were extrapolated. Distributions of 125I/131I-Chlorotoxin were only significant in tumor, stomach, kidneys, and brain (injection site), reflecting non-specific uptake of Chlorotoxin in normal tissues. Mean radiation dose (cGy/37 kBq) was 58.2 for tumor, 17.9 for brains, 1.8 for marrow, 27.1 for stomach, 16.0 for kidneys in mice. For intracranial injection of 370 MBq 131I-Chlorotoxin in patients, extrapolated patient dose (cGy) was 70 for brains, 6 for marrow, 35 for stomach, 60 to kidneys, 227 to tumor, suggesting that 3.7 GBq of 131I-Chlorotoxin can be safely administered to patients. These promising results demonstrated potential in improving patient survival using this novel targeting agent.

RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:523235 CAPLUS

TI Treatment of phosphatidylinositol phospholipid disorders using chlorotoxin or derivatives
IN Gonda, Matthew A.; Alvarez, Vernon L.; Grimes, Carol A.
PA Transmolecular, Inc., USA
SO PCT Int. Appl., 35 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005053611	A2	20050616	WO 2004-US39325	20041123
W:	AE, AG, AL, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SI, TM, TN, TR, TZ, UG, UZ, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG			

P 20031126
AB Disclosed is a method of treating cell proliferative disorders, such as cancer, with ant. of chlorotoxin and/or derivs., analogs of fragments thereof, which are effective to bind to phosphoinositol phospholipids. The p-domain peptide of chlorotoxin, KRGKCYGPGQ, bound to multiple species of phosphatidylinositols, including mono-, bis- and tris-phosphates.

L11 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:971908 CAPLUS

TI Treatment of cell proliferative disorders with chlorotoxin
IN Alvarez, Vernon L.; Gonda, Matthew A.
PA Transmolecular Inc., USA
SO PCT Int. Appl., 94 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003101475	A1	20031211	WO 2003-US17411	20030602
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TZ, UG, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, BG, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2494451	AA	20031211	CA 2003-2494451	20030602
AU 2003237347	A1	20031219	AU 2003-237347	20030602
EP 1539207	A1	20050615	EP 2003-736810	20030602
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
US 2006166892	A1	20060727	US 2005-522810	
PRAI US 2002-384171P	P	20020531		
US 2002-406033P	P	20020827		
WO 2003-US17411	W	20030602		

AB Disclosed is a method of treating cell proliferative disorders, such as cancer, with low doses of chlorotoxin and/or derivs., analogs or fragments thereof, which are effective to inhibit or arrest abnormal cell growth.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:971907 CAPLUS

TI Combination chemotherapy with chlorotoxin for treating cancer
IN Alvarez, Vernon L.; Grimes, Carol A.; Gonda, Matthew A.
PA Transmolecular, Inc., USA
SO PCT Int. Appl., 100 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003101474	A1	20031211	WO 2003-US17410	20030602
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TZ, UG, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, BG, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG			

carcinoma of the lung, Ewing's sarcoma, and metastatic tumors in the brain. Also, diagnostic methods are provided for screening neoplastic neuroectodermal tumors.

RE.CNT 3
THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
DN 1999:330028 CAPLUS
AN 130:335024
TI Method of diagnosing and treating gliomas
IN Ullrich, Nicole; Sontheimer, Harald W.
PA UAB Research Foundation, USA
SO U.S., 34 PP.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

AB This invention includes compns. and methods for combination chemotherapy, particularly involving at least one chemotherapeutic agent used in combination with chlorotoxin or a derivative thereof. A method for detecting the presence of cancer in a patient comprising administering a detectable amount of labeled chlorotoxin or chlorotoxin derivative are also claimed.

RE.CNT 3
THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:756551 CAPLUS
DN 133:307331

TI Diagnosis and treatment of neuroectodermal tumors
IN Sontheimer, Harald J.; Lyons, Susan A.
PA UAB Research Foundation, USA
SO PCT Int. Appl., 56 PP.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

PI WO 2000062807 A1 20001026 20000419
W: AL, AM, AT, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GM, GW, ML, MR, NE, SN, TD, TG
US 2002146749 A1 20021010 US 1999-296031 19990421
US 6667156 B2 20031223
CA 2365533 A2 20011026 20000419
AU 2000044687 A5 20001102 20000419
AU 777209 B2 20041007
EP 1200123 A1 20020502 20000419
EP 1200123 B1 20051102
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CI, AL
JP 2002542206 T2 20021210 JP 2000-611943 20000419
AT 308340 E 20051115 AT 2000-926105 20000419
ES 2253223 T3 20060601 ES 2000-926105 20000419
PRAI US 1999-296031 A 19990421
WO 2000-US10453 W 20000419

AB The present invention provides fusion proteins for the detection and treatment of neuroectodermal tumors. Previous work demonstrated that chlorotoxin is specific for glial-derived or meningioma-derived tumor cells. The current invention has extended the use of chlorotoxin-cytotoxin fusion proteins to treat the whole class neuroectodermal tumors such as gliomas, meningiomas, ependymomas, medulloblastomas, neuroblastomas, gangliomas, pheochromocytomas, melanomas, PNET's, small cell

carcinoma of the lung, Ewing's sarcoma, and metastatic tumors in the brain. Also, diagnostic methods are provided for screening neoplastic neuroectodermal tumors.

RE.CNT 3
THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
DN 1999:330028 CAPLUS
AN 130:335024
TI Method of diagnosing and treating gliomas
IN Ullrich, Nicole; Sontheimer, Harald W.
PA UAB Research Foundation, USA
SO U.S., 34 PP.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

AB The present invention provides a recombinant toxin and monoclonal antibody which specifically binds to glial-derived or meningioma-derived tumor cells. Also provided are various methods of screening for malignant gliomas and meningiomas. Further provided are methods of treating malignant gliomas, including glioblastoma multiforme and astrocytomas.

RE.CNT 2
THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:728115 CAPLUS
DN 130:90192
TI Use of chlorotoxin for targeting of primary brain tumors
AU Sorocanu, Liliana; Gillespie, Yancey; Khazaeli, M. B.; Sontheimer, Harald
CS Departments of Neurobiology, Brain Tumor Research Laboratories, Division of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, 35294, USA
SO Cancer Research (1998), 58(21), 4871-4879
CODEN: CNREAS; ISSN: 0008-5472
PB AACR Subscription Office
DT Journal
LA English
AB Gliomas are primary brain tumors that arise from differentiated glial cells through a poorly understood malignant transformation. Although glioma cells retain some genetic and antigenic features common to glial cells, they show a remarkable degree of antigenic heterogeneity and variable mutations in their genome. Glioma cells have recently been shown to express a glioma-specific chloride ion channel (GCC) that is sensitive to chlorotoxin (CTX), a small peptide purified from *Leiurus quinquestratus* scorpion venom. Using native and recombinant 125I-labeled CTX, we show that toxin binding to glioma cells is

PI US 5905027 A 19990518 US 1996-774154 19961226
US 6028174 A 20000222 US 1997-980388 19971128
US 6319891 B1 20011120 US 1997-980394 19971128
US 2002071841 A1 20020613 US 1997-980395 19971128
US 6429187 B2 20020806
US 2002065216 A1 20020530 US 2001-969618 20011004
US 6870029 B2 20050322
US 2004141981 A1 20040722 US 2003-686782 20031017
US 2005142062 A1 20050630 US 2005-57602 20050215
PRAI US 1995-9283P P 19951227
US 1996-774154 A3 19961226
US 1997-980395 A3 19971128
US 1999-296031 A3 19990421
US 2001-969618 A3 20011004

AB The present invention provides a recombinant toxin and monoclonal antibody which specifically binds to glial-derived or meningioma-derived tumor cells. Also provided are various methods of screening for malignant gliomas and meningiomas. Further provided are methods of treating malignant gliomas, including glioblastoma multiforme and astrocytomas.

RE.CNT 2
THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:728115 CAPLUS
DN 130:90192
TI Use of chlorotoxin for targeting of primary brain tumors
AU Sorocanu, Liliana; Gillespie, Yancey; Khazaeli, M. B.; Sontheimer, Harald
CS Departments of Neurobiology, Brain Tumor Research Laboratories, Division of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, 35294, USA
SO Cancer Research (1998), 58(21), 4871-4879
CODEN: CNREAS; ISSN: 0008-5472
PB AACR Subscription Office
DT Journal
LA English
AB Gliomas are primary brain tumors that arise from differentiated glial cells through a poorly understood malignant transformation. Although glioma cells retain some genetic and antigenic features common to glial cells, they show a remarkable degree of antigenic heterogeneity and variable mutations in their genome. Glioma cells have recently been shown to express a glioma-specific chloride ion channel (GCC) that is sensitive to chlorotoxin (CTX), a small peptide purified from *Leiurus quinquestratus* scorpion venom. Using native and recombinant 125I-labeled CTX, we show that toxin binding to glioma cells is

specific and involves high affinity [dissociation constant (Kd) = 4.2 nM] and low affinity (Kd = 660 nM) binding sites. In radioreceptor assays, 125I-labeled CTX binds to a protein with Mr = 72,000, presumably GCC or a receptor that modulates GCC activity. In vivo targeting and biodistribution expts. were obtained using 125I- and 131I-labeled CTX injected into severe combined immunodeficient mice bearing xenografted gliomas. CTX selectively accumulated in the brain of tumor-bearing mice with calculated brain: muscle ratios of 36.4% of injected dose/g (ID/g), as compared to 12.4% ID/g in control animals. In the tumor-bearing severe combined immunodeficient mice, the vast majority of the brain-associated radioactivity was localized within the tumor (tumor:muscle ratio, 39.13% ID/g; contralateral brain:muscle ratio, 6.88% ID/g). Moreover, 131I-labeled CTX distribution, visualized through in vivo imaging by gamma ray camera scans, demonstrates specific and persistent intratumoral localization of the radioactive ligand. Immunohistochem. studies using biotinylated and fluorescently tagged CTX show highly selective staining of glioma cells in vitro, in situ, and in sections of patient biopsies. Comparison tissues including normal human brain, kidney, and colon were consistently neg. for CTX immunostaining. These data suggest that CTX and CTX-conjugated mols. may serve as glioma-specific markers with diagnostic and therapeutic potential.

RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:505749 CAPLUS
DN 127:119322
TI Method of diagnosing and treating gliomas
IN Sontheimer, Harald W.; Ulrich, Nicole
PA UAB Research Foundation, USA
SO Pat. Int. Appl., 81 PP.
CO:EN: PIXXD2
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9724619	W, AU, CA, JP	19970710	WO 1996-US20403	19961227
CA 2249351	AA	19970710	CA 1996-2249351	19961227
AU 9722399	AI	19970728	AU 1997-22399	19961227
EP 953153	AI	19991103	EP 1996-946129	19961227
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI US 1995-9283P	P	19951227		
WO 1996-US20403	W	19961227		
AB				

The present invention relates generally to the fields of cell physiology, neuro and neuro-oncol. More specifically, the present invention relates to a novel method of detection of the membrane protein "glioma chloride channel" for use as a specific tumor marker for the diagnosis and treatment of gliomas and meningiomas. The invention describes the expression of this chloride conductance with unique properties that selectively characterizes tumor-derived cells of glial origin. Whole-cell patch-clamp techniques were used to characterize the biophys. and pharmacol. properties of chloride channels in primary cultures and acutely isolated cells from biopsies of human astrocytomas and established cell lines.

L11 ANSWER 9 OF 18 USPATFULL on STN
AN 2006:104796 USPATFULL
TI Combination chemotherapy with chlorotoxin
IN Alvarez, Vernon L, Birmingham, AL, UNITED STATES

Gonda, Matthew A, Birmingham, AL, UNITED STATES
Grimes, Carol A, Birmingham, AL, UNITED STATES
US 200608899 AI 20060427
AI US 2003-516079 AI 20030602 (10)
WO 2003-US17410 20030602
PRAI US 2002-384171P 20020531 (60) PCT 371 date
US 2002-406033P 20020827 (60)
DT Utility
FS APPLICATION
LREP MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004, US
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 15 Drawing Page(s)
LN.CNT 2387
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention includes compositions and methods for combination chemotherapy, particularly involving at least one chemotherapeutic agent used in combination with chlorotoxin or a derivative thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 10 OF 18 USPATFULL on STN
AN 2005:164639 USPATFULL
TI Novel method of diagnosing and treating gliomas
IN Sontheimer, Harald W.; Birmingham, AL, UNITED STATES
Ulrich, Nicole, Brookline, MA, UNITED STATES
PI US 2005142062 AI 20050630
AI US 2005-57602 AI 20050215 (11)
RLI Division of Ser. No. US 2001-969618, filed on 4 Oct 2001, GRANTED, Pat. No. US 6870029 Division of Ser. No. US 1997-980395, filed on 28 Nov 1997, GRANTED, Pat. No. US 6429187 Division of Ser. No. US 1996-774154, filed on 26 Dec 1996, GRANTED, Pat. No. US 5905027
PRAI US 1995-9283P 19951227 (60)
DT Utility
FS APPLICATION
LREP MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004, US
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 20 Drawing Page(s)
LN.CNT 1434
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a recombinant toxin and monoclonal antibody which specifically binds to glial-derived or meningioma-derived tumor cells. Also provided are various methods of screening for malignant gliomas and meningiomas. Further provided are methods of treating malignant gliomas, including glioblastoma multiforme and astrocytomas.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 11 OF 18 USPATFULL on STN
AN 2004:184098 USPATFULL
TI Diagnosis and treatment of neuroectodermal tumors
IN Sontheimer, Harald W.; Birmingham, AL, UNITED STATES
Lyons, Susan A.; Monterallo, AL, UNITED STATES
PA UAB Research Foundation (U.S. corporation)
PI US 2004141981 AI 20040722
AI US 2003-686782 AI 20031017 (10)
RLI Division of Ser. No. US 1999-296031, filed on 21 Apr 1999, GRANTED, Pat. No. US 6667156 Continuation-in-part of Ser. No. US 1996-774154, filed on 26 Dec 1996, GRANTED, Pat. No. US 5905027

PRAI US 1995-9283P 19951227 (60)
DT Utility
FS APPLICATION
LREP MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC,
20004
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 15 Drawing Page(s)
LN.CNT 977

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides fusion proteins for the detection and treatment of neuroectodermal tumors. Previous work demonstrated that chlorotoxin is specific for glial-derived or meningioma-derived tumor cells. The current invention has extended the use of chlorotoxin-cytotoxin fusion proteins to treat the whole class neuroectodermal tumors such as gliomas, meningiomas, ependymomas, medulloblastomas, neuroblastomas, gangliomas, pheochromocytomas, melanomas, PPNET's, small cell carcinoma of the lung, Ewing's sarcoma, and metastatic tumors in the brain. Also, diagnostic methods are provided for screening neoplastic neuroectodermal tumors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 12 OF 18 USPATFULL on STN
AN 2003:45283 USPATFULL
TI Compositions and methods relating to glucose metabolism, weight control, and food intake
IN Desir, Gary, Woodbridge, CT, UNITED STATES
PI US 2003032595 A1 20030213
US 6861405 B2 20050301
AI US 2002-167528 A1 20020611 (10)
PRAI US 2001-297547P 20010612 (60)
DT Utility
FS APPLICATION
LREP MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET, PHILADELPHIA, PA, 19103-2921

CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 2823

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to weight control, control of body fat and food intake, and provides useful methods for treating, inter alia, obesity, diabetes and insulin insensitivity, and conditions, diseases, and disorders relating thereto. The invention also relates to methods of identifying useful compounds relating to weight loss, food intake, diabetes, and obesity, among other things, based on the discovery that inhibiting Kvl.3 activity mediates decreased food intake, weight loss, decreased body fat, increase glucose uptake, and increased insulin sensitivity, among other things.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 13 OF 18 USPATFULL on STN
AN 2003:29868 USPATFULL
TI Chlorotoxin inhibition of cell invasion, cancer metastasis, angiogenesis and tissue remodeling
IN Sontheimer, Harold W., Birmingham, AL, UNITED STATES
Garner, Craig C., Birmingham, AL, UNITED STATES
Deahane, Jessy, Hoover, AL, UNITED STATES
PI US 2003021810 A1 20030130
AI US 2002-180420 A1 20020626 (10)

PRAI US 2001-301019P 20010626 (60)
DT Utility
FS APPLICATION
LREP Benjamin Aaron Adler, ADLER & ASSOCIATES, 8011 Candle Lane, Houston, TX, 77071

CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 22 Drawing Page(s)
LN.CNT 111

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods of treating individuals having a pathophysiological conditions that involve the activity of matrix metalloproteinase-2/pro-MMP2 system, comprising the step of: administering to said individual a pharmaceutical composition comprising a pharmaceutically effective dose of chlorotoxin and a pharmaceutically acceptable carrier.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 14 OF 18 USPATFULL on STN
AN 2002:265873 USPATFULL
TI DIAGNOSIS AND TREATMENT OF NEUROECTODERMAL TUMORS
IN LYONS PH.D., SUSAN A., BIRMINGHAM, AL, UNITED STATES
SONTHEIMER, HAROLD W., BIRMINGHAM, AL, UNITED STATES
PI US 2002146749 A1 20021010
US 6667156 B2 20031223
AI US 1999-296031 A1 19990421 (9)
DT Utility
FS APPLICATION
LREP MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004

CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 15 Drawing Page(s)
LN.CNT 977

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides fusion proteins for the detection and treatment of neuroectodermal tumors. Previous work demonstrated that chlorotoxin is specific for glial-derived or meningioma-derived tumor cells. The current invention has extended the use of chlorotoxin-cytotoxin fusion proteins to treat the whole class neuroectodermal tumors such as gliomas, meningiomas, ependymomas, medulloblastomas, neuroblastomas, gangliomas, pheochromocytomas, melanomas, PPNET's, small cell carcinoma of the lung, Ewing's sarcoma, and metastatic tumors in the brain. Also, diagnostic methods are provided for screening neoplastic neuroectodermal tumors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 15 OF 18 USPATFULL on STN
AN 2002:140860 USPATFULL
TI NOVEL METHOD OF DIAGNOSING AND TREATING GLIOMAS
IN SONTHEIMER, HAROLD W., BIRMINGHAM, AL, UNITED STATES
ULLRICH, NICOLE, FAIRFIELD, CT, UNITED STATES
PI US 2002071841 A1 20020613
US 6429187 B2 20020806
AI US 1997-980395 A1 19971128 (8)
RLI Division of Ser. No. US 1996-774154, filed on 26 Dec 1996, GRANTED, Pat. No. US 5905027
DT Utility
FS APPLICATION
LREP MORGAN, LEWIS, AND BOCKIUS LLP, 1800 M STREET, N.W., WASHINGTON, DC, 20036

CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 20 Drawing Page(s)
LN.CNT 1527

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a recombinant toxin and monoclonal antibody which specifically binds to glial-derived or meningioma-derived tumor cells. Also provided are various methods of screening for malignant gliomas and meningiomas. Further provided are methods of treating malignant gliomas, including glioblastoma multiforme and astrocytomas.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 16 OF 18 USPATFULL on STN
AN 2002:126699 USPATFULL
TI Novel method of diagnosing and treating gliomas
IN Sontheimer, Harald W., Birmingham, AL, UNITED STATES
PA Ullrich, Nicole, Fairfield, CT, UNITED STATES
PI The UAB Research Foundation (U.S. corporation)
US 2002065216 A1 20020530
US 6870029 B2 20050322
AI US 2001-969618 A1 20011004 (9)
RLI Division of Ser. No. US 1997-980395, filed on 28 Nov 1997, PENDING
PRAI Division of Ser. No. US 1996-774154, filed on 26 Dec 1996, PATENTED
US 1995-9283P 19951227 (60)
DT Utility
FS APPLICATION
EXNAM MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004

CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 20 Drawing Page(s)
LN.CNT 1533

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a recombinant toxin and monoclonal antibody which specifically binds to glial-derived or meningioma-derived tumor cells. Also provided are various methods of screening for malignant gliomas and meningiomas. Further provided are methods of treating malignant gliomas, including glioblastoma multiforme and astrocytomas.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 17 OF 18 USPATFULL on STN
AN 2001:208857 USPATFULL
TI Method of diagnosing and treating gliomas
IN Sontheimer, Harald W., 1704 Russett Woods Ln., Birmingham, AL, United States 35244
Ullrich, Nicole, 628 Washington St.#3, Brookline, MA, United States 02446
PI US 6319891 B1 20011120
AI US 1997-980394 19971128 (8)
RLI Division of Ser. No. US 1996-774154, filed on 26 Dec 1996, now patented, Pat. No. US 5905027
PRAI US 1995-9283P 19951227 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Huff, Sheela
LREP Morgan, Lewis & Bockius LLP
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 67 Drawing Figure(s): 20 Drawing Page(s)
LN.CNT 1595

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a recombinant toxin and monoclonal antibody which specifically binds to glial-derived or meningioma-derived tumor cells. Also provided are various methods of screening for malignant gliomas and meningiomas. Further provided are methods of treating malignant gliomas, including glioblastoma multiforme and astrocytomas.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 18 OF 18 USPATFULL on STN
AN 2000:21668 USPATFULL
TI Method of diagnosing and treating gliomas
IN Ullrich, Nicole, Fairfield, CT, United States
Sontheimer, Harald W., Birmingham, AL, United States
PA UAB Research Foundation, Birmingham, AL, United States (U.S. corporation)
PI US 6028174 20000222
AI US 1997-980388 19971128 (8)
RLI Division of Ser. No. US 1996-774154, filed on 26 Dec 1996
PRAI US 1995-9283P 19951227 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Hutzell, Paula K.; Assistant Examiner: Sun-Hoffman, Lin
LREP Adler, Benjamin Aaron
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 20 Drawing Figure(s): 20 Drawing Page(s)
LN.CNT 1434

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a recombinant toxin and monoclonal antibody which specifically binds to glial-derived or meningioma-derived tumor cells. Also provided are various methods of screening for malignant gliomas and meningiomas. Further provided are methods of treating malignant gliomas, including glioblastoma multiforme and astrocytomas.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:37:38 ON 03 AUG 2006)

FILE 'REGISTRY' ENTERED AT 12:50:32 ON 03 AUG 2006
L1 5 S MCMPCFTTDHOMARKDDCCGKCKYGPQCLCR/SQEP
L2 5 S MCMPCFTTDHOMARKDDCCGKCKYGPQCLCR/SQEP

FILE 'CAPLUS, USPATFULL, PCTFULL, BIOSIS, SCISEARCH, MEDLINE' ENTERED AT 12:52:22 ON 03 AUG 2006

L3 53 S L2
L4 46 DUP REMO L3 (7 DUPLICATES REMOVED)
L5 18 S L4 AND CANCER
L6 24 S L4 AND TUMOR?
L7 24 S L6 OR L5 AND CHEMOTHERAP?
L8 3 S L6 AND CHEMOTHERAP?
L9 3 S L5 AND CHEMOTHERAP?
L10 18 S L4 AND LABEL?
L11 18 S L10 AND (CANCER OR TUMOR OR MELANOMA OR CARCINOMA OR HODGKIN?)
L12 27 S L4 AND (CANCER OR TUMOR OR MELANOMA OR CARCINOMA OR HODGKIN?)